Literature DB >> 22696717

Profound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient.

K I Quintyne1, P Mainstone, B McNamara, P Boers, F Wallis, R K Gupta.   

Abstract

The authors herein report the case of a 35-year-old woman undergoing adjuvant therapy for node positive breast cancer, who presented with short and rapidly progressive history of bilateral lower limb symptoms of peripheral neuropathy following therapy with paclitaxel. MRI of her neural axis revealed no leptomeningeal enhancement or focal metastatic lesions. Neurophysiological tests favoured toxic sensory axonal polyneuropathy. She remains symptomatic following discontinuation of therapy 20 months ago, and is under review with pain management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22696717      PMCID: PMC3091274          DOI: 10.1136/bcr.12.2010.3645

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Grading of chemotherapy-induced peripheral neuropathy.

Authors:  T J Postma; J J Heimans
Journal:  Ann Oncol       Date:  2000-05       Impact factor: 32.976

2.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.

Authors:  I Ringel; S B Horwitz
Journal:  J Natl Cancer Inst       Date:  1991-02-20       Impact factor: 13.506

3.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Authors:  Marjorie C Green; Aman U Buzdar; Terry Smith; Nuhad K Ibrahim; Vicente Valero; Marguerite F Rosales; Massimo Cristofanilli; Daniel J Booser; Lajos Pusztai; Edgardo Rivera; Richard L Theriault; Cynthia Carter; Debra Frye; Kelly K Hunt; W Fraser Symmans; Eric A Strom; Aysegul A Sahin; William Sikov; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

4.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Authors:  F A Holmes; R S Walters; R L Theriault; A D Forman; L K Newton; M N Raber; A U Buzdar; D K Frye; G N Hortobagyi
Journal:  J Natl Cancer Inst       Date:  1991-12-18       Impact factor: 13.506

5.  Antihistamines in the treatment of taxol-induced paroxystic pain syndrome.

Authors:  A Martoni; C Zamagni; A Gheka; F Pannuti
Journal:  J Natl Cancer Inst       Date:  1993-04-21       Impact factor: 13.506

6.  Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.

Authors:  Elke Persohn; Annalisa Canta; S Schoepfer; Martin Traebert; Lutz Mueller; Alessandra Gilardini; Stefania Galbiati; Gabriella Nicolini; Arianna Scuteri; Francesca Lanzani; Giuditta Giussani; Guido Cavaletti
Journal:  Eur J Cancer       Date:  2005-07       Impact factor: 9.162

7.  Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

Authors:  G Cavaletti; G Bogliun; L Marzorati; A Zincone; M Piatti; N Colombo; D Franchi; M T La Presa; A Lissoni; A Buda; F Fei; S Cundari; C Zanna
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

Review 8.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

Authors:  A D Seidman; C A Hudis; J Albanell; J Albanel; W Tong; I Tepler; V Currie; M E Moynahan; M Theodoulou; M Gollub; J Baselga; L Norton
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

9.  Paclitaxel-induced neuropathy.

Authors:  T J Postma; J B Vermorken; A J Liefting; H M Pinedo; J J Heimans
Journal:  Ann Oncol       Date:  1995-05       Impact factor: 32.976

Review 10.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.